comparemela.com

Latest Breaking News On - Matteo levisetti - Page 1 : comparemela.com

Cue Biopharma, Inc (NASDAQ:CUE) Q3 2023 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.

Dan passeriMatteo levisettiStephen willeyDaniel passeriKerri ann millarReni benjaminRichard dipaolo at saint louis universityFree accounting softwareWashington universityCue biopharma incCue biopharmaCall transcript novemberCue biopharma third quarterChief executiveManish suriChief scientific officer

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms Tumor 1 Positive Cancers at SITC 2023 -November 03, 2023 at 12:01 pm EDT

Overall response rate of 47% and disease control rate of 65% in first line recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® ORR of 56% in patients with low expression of.

United statesSan diegoDan passeriMatteo levisettiJennifer eva selfridgeMaya romanchukChristine chungMarie campinellLifesci communicationsSociety for immunotherapy of cancerMoffitt cancer centerCue biopharma incUniversity hospitals cleveland medical centerCorporate communicationsDepartment of headH lee moffitt cancer center

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line.

United statesMaya romanchuckMatteo levisettiMarie campinellDaniel passeriCorporate communicationsSecurities exchangeCue biopharma incSociety for immunotherapy of cancerDrug administrationLifesci communicationsNeck cancerAnnual meetingFast track designationCue biopharmaWilm tumor

Cue Biopharma, Inc (NASDAQ:CUE) Q2 2023 Earnings Call Transcript

Operator: Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the presentation.

Matteo levisettiKerri millarMichael dustinKaren benjaminDan passeriPiper sandlerTed tenthoffBiggest helium companiesNational academy of scienceMono pharmaceuticalsUniversity of oxfordCue biopharma incSociety for immunotherapy of cancerCue biopharmaCall transcript augustCue biopharma investor update

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, May 09, 2023 Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T. | May 9, 2023

United statesPatrick verheyenPamelad garzoneDaniel passeriMatteo levisettiMarie campinellRafi ahmedCorporate communicationsCue biopharma incSecurities exchangeDrug administrationAmerican society of clinical oncologyOno pharmaceutical co ltdClinical oncologyAnnual meetingOno pharmaceutical

vimarsana © 2020. All Rights Reserved.